Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Sep 15, 2020; 12(9): 1031-1043
Published online Sep 15, 2020. doi: 10.4251/wjgo.v12.i9.1031
Published online Sep 15, 2020. doi: 10.4251/wjgo.v12.i9.1031
Table 2 Remission rates of clinical symptoms in all groups
| Treatment/symptoms | Pre-treatment (n) | Post-treatment (n) | Remission rate |
| Non-surgical treatment (19 cases) | 23 | 7 | 69.6% |
| Abdominal pain | 10 | 4 | |
| Acid reflux | 2 | 0 | |
| Vomiting | 3 | 1 | |
| Bloating | 3 | 1 | |
| Diarrhea | 5 | 1 | |
| Surgical treatment (14 cases) | 12 | 2 | 83.3% |
| Abdominal pain | 5 | 1 | |
| Acid reflux | 2 | 0 | |
| Vomiting | 3 | 0 | |
| Bloating | 1 | 1 | |
| Dizziness | 1 | 0 | |
| Mixed treatment (7 cases) | 8 | 2 | 75.0% |
| Abdominal pain | 4 | 1 | |
| Bloating | 4 | 1 |
- Citation: Wang HH, Liu ZC, Zhang G, Li LH, Li L, Meng QB, Wang PJ, Shen DQ, Dang XW. Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy. World J Gastrointest Oncol 2020; 12(9): 1031-1043
- URL: https://www.wjgnet.com/1948-5204/full/v12/i9/1031.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i9.1031